HCPLive Editorial Staff


Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

Interested in a more traditional, text rundown? 

Top 5 Healthcare Headlines for March 16-23, 2025:

New ACP Guidelines Recommend Adding Triptan to NSAID or Acetaminophen for Migraines


The American College of Physicians now recommends adding a triptan to NSAIDs or acetaminophen for moderate to severe acute migraines and urges clinicians to initiate combination therapy early.

2. 

Automated Insulin Delivery Effectively Lowers HbA1c in Type 2 Diabetes


Tandem Diabetes Care’s Control-IQ+ automated insulin delivery system led to greater HbA1c reduction than continuous glucose monitoring alone in adults with insulin-requiring type 2 diabetes.

3. 

FDA Approves Guselkumab (Tremfya) For Crohn's Disease


The FDA approved guselkumab for moderately to severely active Crohn’s disease based on phase 3 trial data demonstrating superior efficacy over ustekinumab on endoscopic endpoints.

4. 

FDA Approves Oral Iptacopan (Fabhalta) as First C3 Glomerulopathy Therapy


The FDA approved iptacopan as the first therapy for C3 glomerulopathy, with phase 3 data showing significant proteinuria reduction and sustained efficacy at 12 months.

5. 

FDA Approves Vutrisiran (AMVUTTRA) for ATTR-CM


The FDA expanded vutrisiran’s approval for cardiomyopathy in transthyretin-mediated amyloidosis, making it the first RNAi therapeutic to reduce cardiovascular mortality and hospitalizations in ATTR-CM.






Podcasts

An audio recap of the top 5 stories in healthcare news from the week of 03/16-03/23.

HCPLive 5 Stories in Under 5: Week of 03/16

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know—whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories focused on new migraine guidelines from the American College of Physicians (ACP), the benefits of automated insulin delivery (AID) for insulin-requiring type 2 diabetes, and a trio of recent US Food and Drug Administration approvals for Crohn’s disease, C3 glomerulopathy, and transthyretin amyloid cardiomyopathy (ATTR-CM).

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here’s your quick dive into the top stories for the week of March 16, 2025—let’s jump in!

Interested in oncology news? Check out The 

New recommendations from the American College of Physicians (ACP) now recommend adding a triptan to nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen to treat moderate to severe acute episodic migraine headaches. Based on the ACP’s evaluation of migraine pharmacologic treatments, this updated guideline recommends clinicians counsel their patients to initiate combination therapy urgently after the onset of an acute migraine headache.

Automated insulin delivery (AID) with Tandem Diabetes Care’s Control-IQ+ technology led to a superior reduction in hemoglobin A1c (HbA1c) than continuous glucose monitoring (CGM) alone in adults with insulin-requiring type 2 diabetes (T2D). At 13 weeks, the mean HbA1c levels decreased by 0.9% with AID and by 0.3% in the control group (

For further insight into the algorithm’s recent clearance, check out a recent 

 featuring Laurel Messer, PhD, RN, senior director of medical affairs at Tandem Diabetes Care.

The FDA approved Johnson & Johnson’s guselkumab (Tremfya) for the treatment of adults with moderately to severely active Crohn's disease. According to data from multiple phase 3 trials, including the GALAXI trials, guselkumab outperformed ustekinumab (Stelara) on multiple endoscopic endpoints. Guselkumab now boasts indications for moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis (UC).

The FDA approved Novartis’ oral iptacopan (Fabhalta) for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, marking the first approval for the ultra-rare kidney disease. Based on data from the phase 3 APPEAR-C3G trial, iptacopan reduced the 24-hour urine protein-to-creatinine ratio (UPCR) by 35.1% (

 =.0014), with sustained reductions at 12 months.

The FDA approved Alnylam’s supplemental New Drug Application (sNDA) for vutrisiran (AMVUTTRA) for the treatment of adults with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). With this expanded indication, vutrisiran becomes the first approved RNAi therapeutic targeted to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits in ATTR-CM.

Articles

The American College of Physicians has updated migraine treatment guidelines, recommending the addition of triptans to NSAIDs or acetaminophen for acute episodes. Automated insulin delivery (AID) systems have shown significant HbA1c reduction in type 2 diabetes patients compared to continuous glucose monitoring alone. The FDA has approved guselkumab for Crohn's disease, iptacopan for C3 glomerulopathy, and vutrisiran for transthyretin amyloid cardiomyopathy. These approvals highlight advancements in treatment options for complex conditions, offering new therapeutic avenues for patients and healthcare providers.

Our top 5 headlines featured new migraine guidelines, the benefit of automated insulin delivery for type 2 diabetes, and 3 key FDA decisions.

The HCPFive: Top News for Healthcare Providers from the Week of 03/16

 respond well to treatment, long-term management is essential due to the potential for recurrence and malignant transformation.

 stress the need for individualized follow-up based on patient-specific risk factors, including lesion burden, history of nonmelanoma skin cancer, and degree of sun damage.

 Patients with extensive AKs or immunosuppression, such as organ transplant recipients, require closer monitoring due to their heightened risk of progression to squamous cell carcinoma (SCC).

In addition to surveillance, patient education is a critical component of long-term AK management. Clinicians should provide guidance on self-examinations, early detection of suspicious lesions, and the importance of continued sun protection. The guidelines also address special considerations for immunosuppressed patients, who may require more aggressive treatment approaches and more frequent dermatologic assessments.

This quiz will assess knowledge of post-treatment surveillance strategies, risk stratification, and best practices for long-term follow-up and patient education in AK management.

B) The patient’s risk of progression to SCC

D) Whether the patient has a history of acne

A) A patient with extensive AKs on the face

B) A patient with severe pain from AK lesions

C) A patient with limited life expectancy

Editor's Note: This quiz was created with the assistance of artificial intelligence tools.

Eisen DB, Dellavalle RP, Frazer-Green L, Schlesinger TE, Shive M, Wu PA. Focused update: Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2022;87(2):373-374.e5. doi:10.1016/j.jaad.2022.04.013

Long-term management of actinic keratosis (AK) is crucial due to the risk of recurrence and malignant transformation. The American Academy of Dermatology's 2021 guidelines emphasize individualized follow-up based on risk factors like lesion burden and sun damage. Patients with extensive AKs or immunosuppression need closer monitoring due to higher progression risk to squamous cell carcinoma. Patient education on self-examinations and sun protection is vital. Immunosuppressed patients may require aggressive treatment and frequent assessments. The guidelines highlight post-treatment surveillance, risk stratification, and best practices for long-term follow-up.

This quiz, the fourth in this series, assesses your knowledge in post-AK treatment surveillance strategies, risk stratification, and more.


Clinical Quiz: Actinic Keratosis Follow-Up Recommendations from 2021 AAD Guidelines

 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

Interested in a more traditional, text rundown? 

Top 5 Healthcare Headlines for March 9-16, 2025:

CagriSema Yields Nearly 16% Weight Loss in Phase 3 REDEFINE 2 Trial


In the Phase 3 REDEFINE 2 trial, CagriSema showed weight reduction in adults with obesity or overweight and type 2 diabetes, outperforming placebo.



Lorundrostat Significantly Lowers Blood Pressure in Key Hypertension Trials


The Phase 3 Launch-HTN and Phase 2 Advance-HTN trials showed lorundrostat effectively reduced blood pressure in uncontrolled or resistant hypertension with a favorable safety profile.



PharmaTher Receives New Early June FDA Goal Date for Ketamine


PharmaTher announced the FDA set a new Priority Review goal date of June 4, 2025, for ketamine to treat anesthesia, pain, mental health, and neurological conditions.



FDA Awards Fast Track Designation to ATSN-201 Gene Therapy for XLRS


The FDA granted Fast Track designation to ATSN-201 for X-linked retinoschisis, allowing Atsena Therapeutics to seek Priority Review for their gene therapy.



FDA Approves First Interchangeable Biosimilar for Omalizumab


The FDA approved omalizumab-igec (OMLYCLO) as the first interchangeable biosimilar to Xolair for asthma, CRSwNP, IgE-mediated food allergy, and CSU.

An audio recap of the top 5 stories in healthcare news from the week of 03/09-03/16